

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.3	28.09.2024	59344-00026	Date of first issue: 16.02.2015

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier Trade name	:	Letermovir Solid Formulation
1.2	Relevant identified uses of th	e s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture		Pharmaceutical
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
	Company	:	MSD Kilsheelan Clonmel Tipperary, IE
	Telephone	:	353-51-601000
	E-mail address of person	:	EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

responsible for the SDS

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 2
Specific target organ toxicity - repeated
exposure, Category 2

H361d: Suspected of damaging the unborn child. H373: May cause damage to organs through prolonged or repeated exposure.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms

Signal word	:	Warning
Hazard statements	:	H361d Suspected of damaging the unborn child. H373 May cause damage to organs through prolonged or repeated exposure.

:

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.3	28.09.2024	59344-00026	Date of first issue: 16.02.2015

Precautionary statements

Prevention:

P201 Obtain special instructions before use.
P260 Do not breathe dust.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Hazardous components which must be listed on the label: Letermovir

2

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Letermovir	917389-32-3	Repr. 2; H361d STOT RE 2; H373 (Liver, spleen, Blood)	>= 30 - < 50

For explanation of abbreviations see section 16.



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.3	28.09.2024	59344-00026	Date of first issue: 16.02.2015

SECTION 4: First aid measures

4.1 Description of first aid meas	sures	3
General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
4.2 Most important symptoms a	and e	ffects, both acute and delayed
Risks	:	Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure.
		Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
4.3 Indication of any immediate	med	lical attention and special treatment needed
Treatment	:	Treat symptomatically and supportively.
SECTION 5: Firefighting mea	asure	9S
E 4 Entinemain him or months		

5.1 Extinguishing media

Suitable extinguishing media	:	Water spray
		Alcohol-resistant foam
		Carbon dioxide (CO2)
		Dry chemical



Versio 4.3	on	Revision Date: 28.09.2024		0S Number: 344-00026	Date of last issue: 06.04.2024 Date of first issue: 16.02.2015
	Unsuita media	ble extinguishing	:	None known.	
5.2 S	pecial	hazards arising from	the	substance or mi	xture
	Specific fighting	hazards during fire-	:	concentrations, a potential dust exp	dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a plosion hazard. pustion products may be a hazard to health.
	Hazardous combustion prod- ucts		:	Carbon oxides Metal oxides Nitrogen oxides (NOx)
5.3 A	dvice	or firefighters			
	Special for firefi	protective equipment ghters	:		e, wear self-contained breathing apparatus. tective equipment.
	Specific ods	extinguishing meth-	:	cumstances and Use water spray	g measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. ged containers from fire area if it is safe to do

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
2 Environmental precautions		

6.2 Environmental precautions

Environmental precautions :	Avoid release to the environment.
	Prevent further leakage or spillage if safe to do so.
	Retain and dispose of contaminated wash water.
	Local authorities should be advised if significant spillages
	cannot be contained.

6.3 Methods and material for containment and cleaning up

Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces es, as these may form an explosive mixture if they are re- leased into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and dis-	suitable con-	ethods for cleaning up		
es, as these may form an explosive mixture if they are re- leased into the atmosphere in sufficient concentration.	t in the air (i.e., clearing dust surfaces			
posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter	they are re- ntration. ases and dis- Is and items			



Letermovir Solid Formulation

Version 4.3	Revision Date: 28.09.2024	SDS Number: 59344-00026	Date of last issue: 06.04.2024 Date of first issue: 16.02.2015							
		Sections 13 a	gulations are applicable. nd 15 of this SDS provide information regarding r national requirements.							
6.4 Reference to other sections See sections: 7, 8, 11, 12 and 13.										
SECTION 7: Handling and storage										
7.1 Preca	utions for safe handlin	g								
	nical measures	causing an ex Provide adequ and bonding,	uate precautions, such as electrical grounding or inert atmospheres.							
	/Total ventilation e on safe handling	: Do not breath Do not swallor Avoid contact Avoid prolong Handle in acc practice, base sessment Minimize dust Keep containe Keep away fro Take precauti	w. with eyes. ed or repeated contact with skin. ordance with good industrial hygiene and safety ed on the results of the workplace exposure as- generation and accumulation. er closed when not in use. om heat and sources of ignition. onary measures against static discharges.							
Hygiene measures		 environment. If exposure to flushing syste place. When unated clothing The effective of engineering co appropriate de industrial hygi 	chemical is likely during typical use, provide eye ms and safety showers close to the working using do not eat, drink or smoke. Wash contami- before re-use. operation of a facility should include review of ontrols, proper personal protective equipment, egowning and decontamination procedures, ene monitoring, medical surveillance and the strative controls.							
7.2 Conditions for safe storage, including any incompatibilities										
Requ	irements for storage and containers	: Keep in properly labelled containers. Store locked up. accordance with the particular national regulations.								
Advic	e on common storage	: Do not store v Strong oxidizi	vith the following product types: ng agents							
7.3 Specif	fic end use(s)									
-	ific use(s)	: No data availa	able							



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.3	28.09.2024	59344-00026	Date of first issue: 16.02.2015

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Dust

5 mg/m3 Value type (Form of exposure): TWA (respirable dust) Basis: FOR-2011-12-06-1358

10 mg/m3 Value type (Form of exposure): TWA (total dust) Basis: FOR-2011-12-06-1358

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Letermovir	917389-32- 3	TWA	0.4 mg/m3 (OEB 2)	Internal
Silicon dioxide	7631-86-9	TWA (respirable dust)	1,5 mg/m3 (Silica)	FOR-2011- 12-06-1358

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health ef- fects	Value
Silicon dioxide	Workers	Inhalation	Long-term systemic effects	4 mg/m3

8.2 Exposure controls

Engineering measures

Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection		
Material	:	Chemical-resistant gloves
Skin and body protection	:	Work uniform or laboratory coat.
Respiratory protection	:	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to NS EN 143
Filter type	:	Particulates type (P)



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.3	28.09.2024	59344-00026	Date of first issue: 16.02.2015

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	powder
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, han- dling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
рН	:	No data available
Viscosity Viscosity, kinematic	:	Not applicable
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n- octanol/water	:	Not applicable
Vapour pressure	:	Not applicable
Relative density	:	No data available
Density	:	No data available



Letermovir Solid Formulation

Versi 4.3	ion	Revision Date: 28.09.2024		DS Number: 344-00026	Date of last issue: 06.04.2024 Date of first issue: 16.02.2015
I	Relativ	e vapour density	:	Not applicable	
Particle characterist Particle size			:	No data availabl	e
9.2 Other information Explosives		:	Not explosive		
	•	ng properties	:		or mixture is not classified as oxidizing.
Evaporation rate			:	Not applicable	

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions	:	May form explosive dust-air mixture during processing, han- dling or other means. Can react with strong oxidizing agents.
10.4 Conditions to avoid		
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
10.5 Incompatible materials		
Materials to avoid	:	Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Eye contact

Information on likely routes of	:	Inhalation
exposure		Skin contact
		Indestion

Acute toxicity

Not classified based on available information.

Components:

Letermovir:

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

Versior 4.3	-	vision Date: 09.2024	-	S Number: 344-00026	Date of last issue: 06.04.2024 Date of first issue: 16.02.2015
Ac	Acute oral toxicity		:	LD50 (Rat): > 2.00	00 mg/kg
				LD50 (Mouse): > 2	2.000 mg/kg
		sion/irritation ed based on availa	ble	information.	
<u>Cc</u>	omponer	<u>nts:</u>			
	e termovi i emarks	:	:	No data available	
	-	e damage/eye irri ed based on availa			
<u>Cc</u>	omponer	<u>nts:</u>			
	Letermovir: Remarks			No data available	
Re	espirator	y or skin sensitis	atio	n	
No Re	espirator	ed based on availa y sensitisation			
		ed based on availa	ble	information.	
	Components:				
	Letermovir: Remarks			No data available	
	Germ cell mutagenicity Not classified based on available information.				
<u>Co</u>	Components:				
	etermovii				
Ge	enotoxicit	y in vitro	:	Test Type: Bacter Result: negative	ial reverse mutation assay (AMES)
				Test Type: Chrom Result: negative	nosome aberration test in vitro
Ge	enotoxicit	y in vivo	:	cytogenetic assay Species: Mouse	nalian erythrocyte micronucleus test (in vivo /) : Intraperitoneal injection
Ge	erm cell n	nutagenicity- As-	:	Weight of evidenc	e does not support classification as a germ

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

Version 4.3	Revision Date: 28.09.2024	SDS Number: 59344-00026	Date of last issue: 06.04.2024 Date of first issue: 16.02.2015				
ses	sment	cell mutager	cell mutagen.				
	cinogenicity classified based on avail	able information.					
-	productive toxicity pected of damaging the u	unborn child.					
<u>Cor</u>	nponents:						
	ermovir: octs on fertility	Species: Rat Application F Fertility: NO					
		Species: Rat Application F Fertility: LOA Result: No e					
		Species: Mo Application F Fertility: NO					
Effe mer	ects on foetal develop- nt	Species: Rat Developmen Result: Emb	imbryo-foetal development t tal Toxicity: LOAEL: 250 mg/kg body weight ryo-foetal toxicity aternal toxicity observed.				
		Species: Ral Developmen Result: Emb Abortion	imbryo-foetal development bbit tal Toxicity: LOAEL: 225 mg/kg body weight ryo-foetal toxicity, Malformations were observed., aternal toxicity observed.				
•	productive toxicity - As- sment	: Some evider animal expe	nce of adverse effects on development, based on riments.				

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

Version 4.3	Revision Date: 28.09.2024	SDS Number: 59344-00026	Date of last issue: 06.04.2024 Date of first issue: 16.02.2015
<u>Com</u>	ponents:		
Leter	movir:		
Expo	sure routes	: Ingestion	
	et Organs	: Liver, spleen,	Blood
Asse	ssment	: May cause da exposure.	amage to organs through prolonged or repeated
Repe	ated dose toxicity		
Com	ponents:		
Leter	movir:		
Spec	ies	: Mouse	
NOA	EL	: 40 mg/kg	
LOAE		: 100 mg/kg	
	cation Route	: Oral	
	sure time	: 13 Weeks	
Targe	et Organs	: Liver, spleen	
Spec		: Rat	
NOA		: 150 mg/kg	
	cation Route	: Oral	
Expo Rema	sure time	: 26 Weeks	t advarsa offacts ware reported
Rema		. No significan	t adverse effects were reported
Spec	ies	: Monkey	
NOA		: 100 mg/kg	
LOAE		: 200 - 250 mg	/kg
	cation Route sure time	: Oral : 39 Weeks	
	et Organs	: Kidney	
raige	or organo	. Rianoy	
Spec		: Rat	
NOA		: 60 mg/kg	
LOAE		: 180 mg/kg	
	sure time et Organs	: 13 Weeks	, Liver, spleen, Immune system
raige	organs	. 16303, 01000	, Liver, spieeri, ininune system
Spec		: Monkey	
NOA		: 30 mg/kg	
LOAE		: 100 mg/kg	
	cation Route	: Oral	
	sure time	: 4 Weeks : Blood	
rarge	et Organs	. DIUUU	

Aspiration toxicity

Not classified based on available information.



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.3	28.09.2024	59344-00026	Date of first issue: 16.02.2015

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Letermovir:

Ingestion	:	Symptoms: Diarrhoea, Nausea, Vomiting, Headache, Dizzi-
		ness, Fatigue, Back pain, Oedema, Rash, muscle pain

SECTION 12: Ecological information

12.1 Toxicity

Components:		
Letermovir:		
Toxicity to fish	:	LC50 (Menidia beryllina (Silverside)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Americamysis): 16 mg/l Exposure time: 96 h
		EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 8,8 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
		NOEC (Pseudokirchneriella subcapitata (green algae)): 8,8 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to microorganisms	:	EC50 : > 972 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

Version 4.3	Revision Date: 28.09.2024		OS Number: 344-00026	Date of last issue: 06.04.2024 Date of first issue: 16.02.2015
			NOEC : 29,6 mg/ Exposure time: 3 Test Type: Respi Method: OECD T	h
Toxicity to fish (Chronic tox- icity)		:	Method: OECD T	2 d ales promelas (fathead minnow) est Guideline 210 city at the limit of solubility
aqua	Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)			1 d a magna (Water flea) est Guideline 211
12.2 Pers	istence and degradabil	ity		
Com	ponents:			
	rmovir: egradability	:	Result: rapidly de Biodegradation: Exposure time: 6	50 %
12.3 Bioa	ccumulative potential			
Com	ponents:			
Parti	rmovir: tion coefficient: n- nol/water	:	log Pow: 2,29	
12.4 Mob	ility in soil			
<u>Com</u>	ponents:			
Distr	r movir: bution among environ- al compartments	:	log Koc: 3,46	

12.5 Results of PBT and vPvB assessment

Product:	
Assessment	: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.3	28.09.2024	59344-00026	Date of first issue: 16.02.2015

12.6 Endocrine disrupting properties

Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods	
Product	 Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	 Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.2 UN proper shipping name		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.3 Transport hazard class(es)		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good



Letermovir Solid Formulation

Version 4.3	Revision Date: 28.09.2024	-	DS Number: 9344-00026	Date of last issue: 06.04.2024 Date of first issue: 16.02.2015			
RID		:	Not regulated as	a dangerous good			
IMDG		:	Not regulated as a dangerous good				
ΙΑΤΑ		:	Not regulated as a dangerous good				
14.4 Packi	ing group						
ADN		:	Not regulated as	a dangerous good			
ADR		:	Not regulated as	a dangerous good			
RID		:	Not regulated as	a dangerous good			
IMDG		:	Not regulated as	a dangerous good			
ΙΑΤΑ	(Cargo)	:	Not regulated as	a dangerous good			
ΙΑΤΑ	(Passenger)	:	Not regulated as	a dangerous good			
14.5 Environmental hazards							
Not regulated as a dangerous good							
14.6 Special precautions for user Not applicable							

14.7 Maritime transport in bulk according to IMO instruments

emarks
emarks

: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	:	Not applicable			
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable			
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable			
Regulation (EC) on substances that deplete the ozone layer	:	Not applicable			
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	:	Not applicable			
Regulation (EU) No 649/2012 of the European Parlia- ment and the Council concerning the export and import of dangerous chemicals	:	Not applicable			
Seveso III: Directive 2012/18/EU of the European Parliament and of the Council					

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the working environment.

Note the regulation on organization, leadership and participation, chapter 12 on the work of



Letermovir Solid Formulation

Version 4.3	Revision Date: 28.09.2024	SDS Number: 59344-00026	Date of last issue: 06.04.2024 Date of first issue: 16.02.2015				
child	children and young people.						
The components of this product are reported in the following inventories:							
AICS		: not determined	ł				
DSL		: not determined	t				
IECS	C	: not determined	t				
15.2 Chemical safety assessment A Chemical Safety Assessment has not been carried out. SECTION 16: Other information							
	r information	: Items where c	 Items where changes have been made to the previous version are highlighted in the body of this document by two vertical 				
Full text of H-Statements							
H361 H373	-		damaging the unborn child. mage to organs through prolonged or repeated allowed.				
Full	Full text of other abbreviations						
			organ toxicity - repeated exposure pational Exposure limits				

FOR-2011-12-06-1358 / : Long term exposure limit

FOR-2011-12 TWA

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory: LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic sub-



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.3	28.09.2024	59344-00026	Date of first issue: 16.02.2015

stance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/		
Classification of the mixtur	e:		Classification procedure:	
Repr. 2	H3(61d	Calculation method	
STOT RE 2	H3	73	Calculation method	

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN